本研究旨在对血液系统恶性肿瘤患者新型冠状病毒肺炎病毒（SARS-CoV-2）感染后死亡风险进行量化分析，根据病毒变异和恶性肿瘤类型进行分层。通过丹麦全国性登记，我们对在SARS-CoV-2检测阳性之前的5年内收到血液系统恶性肿瘤出院诊断的个体进行一项基于人群的队列研究（2020年2月至2023年4月）。在阳性检测后的30天内跟踪所有个体，并计算总体和时间分层的病例死亡风险（CFR）。 我们确定了7154名有血液系统恶性肿瘤史的感染SARS-CoV-2的个体。其中，我们观察到223例死亡，导致CFR为3.1%。CFR在流行初期最高（10%），并在Omicron BA1/BA2变异主导时期逐渐下降至1.9%。相较于淋巴瘤（CFR 3%），急性白血病患者的CFR最高（CFR 6.2%，调整后相对风险为1.95，95%置信区间1.33-2.88）。 我们观察到CFR随时间推移而降低，这可能归因于新治疗方法、COVID-19疫苗接种以及较不具侵袭性变异的出现。 © 2023 John Wiley & Sons Ltd.发表于《欧洲血液学杂志》的文章。

We aimed to quantify the risk of death following a positive test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among individuals with haematological malignancies, stratified by virus variants and type of malignancy.Using the Danish nationwide registries, we conducted a population-based cohort study among individuals who received a discharge diagnosis of haematological malignancies during the 5 years prior to testing positive for SARS-CoV-2 (February 2020-April 2023). All individuals were followed for 30 days after a positive test, and overall and time-stratified case fatality risks (CFR) were estimated.We identified 7154 individuals with a history of haematological malignancies who tested positive for SARS-CoV-2. Among these, we observed 223 deaths, yielding a CFR of 3.1%. The CFR was highest at the beginning of the pandemic (10%) and gradually declined to 1.9% during the period of Omicron BA1/BA2 predominance. The highest CFR was observed among individuals with acute leukaemia (CFR 6.2%, adjusted relative risk 1.95, 95% confidence interval 1.33-2.88) compared to individuals with lymphoma (CFR 3%).We observed a reduction in the CFR over time, which may be attributed to new treatments, COVID-19 vaccination and the emergence of less aggressive variants.© 2023 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.